Form 4: Nurix Legal Chief Exercises, Sells Shares Under 10b5-1 Plan

Nurix Therapeutics' Chief Legal Officer, Christine Ring, exercised stock options and immediately sold the acquired shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc., executed a stock transaction on January 20, 2026.
• She acquired 3,760 shares of common stock by exercising employee stock options at a price of $1.86 per share.
• Concurrently, she sold all 3,760 shares of common stock at a weighted average price of $18.4237 per share, with individual sales ranging from $18.18 to $18.69.
• These transactions were conducted pursuant to a pre-established Rule 10b5-1 trading plan.
• Following these transactions, Christine Ring beneficially owns 50,897 shares of common stock and 8,643 employee stock options.

Sentiment

Score: 5

Explanation: The transaction is neutral to slightly negative. While it's an insider sale, the execution under a Rule 10b5-1 plan mitigates concerns about it being based on new negative information. It represents a routine liquidity event for an executive.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on recent non-public information.
• The significant difference between the option exercise price of $1.86 and the sale price of $18.4237 demonstrates a substantial gain for the executive on these specific shares.

Negatives

• An insider sale, even when part of a 10b5-1 plan, reduces the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

This transaction is a routine insider equity transaction, common across all industries for executives managing their personal portfolios and compensation. It does not provide specific insights into broader industry trends for biotechnology or pharmaceuticals.

Related Party Transactions

• Christine Ring, Chief Legal Officer, exercised stock options and sold shares of Nurix Therapeutics, Inc. common stock.

Stakeholder Impact

• Shareholders may view the insider sale as a slight negative, though the 10b5-1 plan context reduces concerns about its implications for company performance. The transaction itself does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise and sale) executed under a Rule 10b5-1 plan. This type of transaction is typically pre-scheduled and does not signal new material information about the company's prospects. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a 'hold' position if already invested, or 'na' if no prior position, as it offers no new fundamental insight for a 'buy' or 'sell' decision.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Christine Ring, Chief Legal Officer, 10b5-1 Plan, Equity Transaction